JPM vs VERA Stock Comparison
Compare JPM and VERA across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between JPM and VERA?
JPM leads the current stock comparison as JPMorgan Chase & Co., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
JPMorgan Chase & Co. vs Vera Therapeutics, Inc.
JPM leads
JPM leads by 11 AIQ points, primarily on Quality and Risk Resilience, but the lead has narrowed from 16 points over 30 sessions. Wall Street currently favors VERA on target upside.
Competitive: 4 of 5 evidence groups support JPM, its lead is narrowing, and its current signal state is conflicted.
JPMorgan Chase & Co.
Vera Therapeutics, Inc.
The Algovestiq AIQ Score currently favors JPM over VERA, 52 versus 41 as of Sep 11, 2026. JPM's advantage is driven primarily by stronger quality and risk resilience. JPM also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors VERA. 4 of 5 covered evidence groups favor JPM today, and the comparison is rated Competitive on stability: the leader's advantage has been narrowing. JPM lead: Weakening — the AIQ differential moved from 16 to 11 points over 30 sessions.
Compare JPMorgan Chase & Co. and Vera Therapeutics, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare JPM and VERA against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality46 vs 27JPM +19
- Risk Resilience69 vs 56JPM +13
- Momentum61 vs 49JPM +12
4 of 5 evidence groups favor JPM. JPM’s edge is concentrated in quality and risk resilience.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum +5
No new signals fired.
Largest factor move: Momentum +2
New signals
- Bollinger Band Squeeze — neutral, volatility, short horizon
JPM's lead was unchanged in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — JPM and VERA both carry a full feed there.
The central trade-off
JPM (JPMorgan Chase & Co.): the stronger current systematic profile, led by quality and risk resilience.
VERA (Vera Therapeutics, Inc.): the counter-case, on analyst expectations — but at materially higher volatility, 59.6% against 14.2%.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
JPMJPM on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
JPMJPM on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
JPMJPM on the Momentum factor, by 12 points.
Lower downside
JPMJPM on Risk Resilience, by 13 points.
Analyst upside
VERAVERA on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors JPM, analyst targets favor VERA. That disagreement is the most useful thing on this page.
| Measure | JPM | VERA | Note |
|---|---|---|---|
| Implied upside to target | +1.4% | +147.5% | VERA has more room |
| Target dispersion | +34.6% | +94.5% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 11 | 8 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 5 covered evidence groups favor JPM. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | JPM | 52 vs 41 |
| Fundamentals | JPM | EPS growth 27.6% vs 10.1%; TTM ROE 17.8% vs -84.1% |
| Valuation | Not covered | Not covered |
| Technicals | JPM | Price vs 50-day 1.4% vs -0.9%; vs 200-day 10.8% vs -15% |
| Risk Resilience | JPM | Risk Resilience 69 vs 56 |
| Analyst expectations | VERA | Target upside 1.4% vs 147.5% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of JPM and VERA and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is moderate at 11 points.
- 4 of 5 covered evidence groups point the same way. (supports the conclusion holding)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on JPM.
How the comparison changed
119 daily snapshots · May 4 – Sep 10JPM lead: Weakening — the AIQ differential moved from 16 to 11 points over 30 sessions.
- Today
- JPM +11
- 52 vs 41
- 7 sessions ago
- JPM +3
- 52 vs 49
- 30 sessions ago
- JPM +16
- 54 vs 38
- 90 sessions ago
- JPM +4
- 56 vs 52
The lead changed hands 2 times in this window, most recently on May 15 when JPM moved ahead of VERA.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
3 bullish / 1 bearish, conflicted
- Golden Cross Active — bullish, trend, long horizon (10.07%)
- EMA Ribbon Expansion Bullish — bullish, trend, medium horizon
- Uptrend Structure Active — bullish, trend, long horizon
1 bullish / 2 bearish / 2 neutral, conflicted
- Death Cross Active — bearish, trend, long horizon (11.76%)
- Bollinger Band Squeeze — neutral, volatility, short horizon
- Downtrend Structure Active — bearish, trend, long horizon
JPM leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price and the AIQ Score both moved up over the latest session (price +0.76%, AIQ +1 points).
Price and the AIQ Score both moved up over the latest session (price +4.32%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1VERA closes the Quality gap — currently 19 points behind, the largest single contributor to JPM's edge.
- 2VERA's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3JPM's conflicting signal state resolves bearish — it currently carries 3 bullish and 1 bearish rules at once.
- 4The narrowing continues — the lead has already given back 5 points over 30 sessions, and a further 11-point move would eliminate JPM's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
JPM leads on balance| Metric | JPM | VERA |
|---|---|---|
| Revenue growth (YoY) | 11.9% | 0% |
| EPS growth (YoY) | 27.6% | 10.1% |
| Gross margin | 62.6% | 0% |
| Operating margin | 28.2% | 0% |
| Return on equity (TTM) | 17.8% | -84.1% |
| Debt to equity | 3.3 | 0.18 |
Performance
JPM leads 4 of 6 windows| Metric | JPM | VERA |
|---|---|---|
| 1 week (5 sessions) | -0.7% | -5.8% |
| 1 month (20 sessions) | -3.2% | 12% |
| 3 months (63 sessions) | 14.4% | 6.3% |
| 6 months (126 sessions) | 23% | -20.1% |
| Year to date | 9.7% | -33.6% |
| 1 year (252 sessions) | 20.7% | 37.9% |
Technicals
JPM has the stronger structure| Metric | JPM | VERA |
|---|---|---|
| RSI (14) | 53.2 | 58.5 |
| ADX (14) | 11 | 19 |
| Price vs 50-day | 1.4% | -0.9% |
| Price vs 200-day | 10.8% | -15% |
| Volatility (1M, annualized) | 14.2% | 59.6% |
Risk
JPM is the more resilient| Metric | JPM | VERA |
|---|---|---|
| Beta | 0.79 | 1.13 |
| Sharpe ratio | 0.71 | 0.72 |
| Sortino ratio | 0.99 | 1.43 |
| Max drawdown | -15.5% | -48.1% |
| Current drawdown | -3.2% | -39.6% |
| Annualized volatility | 22.1% | 59.4% |
| Value at risk (95%) | -2.3% | -4.5% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, JPM or VERA?
On the Algovestiq AIQ Score, JPM is the stronger of the two as of Sep 11, 2026, scoring 52 against VERA's 41. The edge comes from quality and risk resilience. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is JPM or VERA the better buy right now?
JPM carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Competitive — 4 of 5 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor JPM over VERA?
The composite weights Quality, Value, Momentum and Risk Resilience. JPM leads Quality by 19 points; JPM leads Risk Resilience by 13 points; JPM leads Momentum by 12 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, JPM or VERA?
Analyst price targets imply +1.4% upside for JPM and +147.5% for VERA, so the Street currently favors VERA. That points the opposite way to the AIQ Score, which favors JPM. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, JPM or VERA?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, JPM or VERA?
JPM on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, JPM or VERA?
JPM on the Momentum factor, by 12 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, JPM or VERA?
JPM is the more resilient of the two, so the other name carries the higher downside risk. JPM on Risk Resilience, by 13 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is JPM more profitable than VERA?
JPM leads on the comparable margin measures — gross margin 62.6% vs 0%; operating margin 28.2% vs 0%; ttm roe 17.8% vs -84.1%.
Is JPM's lead over VERA getting stronger or weaker?
JPM lead: Weakening — the AIQ differential moved from 16 to 11 points over 30 sessions. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has changed hands 2 times in that window, most recently on 2026-05-15, when JPM moved ahead of VERA.
What would change the JPM vs VERA verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: VERA closes the Quality gap — currently 19 points behind, the largest single contributor to JPM's edge; VERA's Death Cross Active resolves — a bearish trend rule currently active against it; JPM's conflicting signal state resolves bearish — it currently carries 3 bullish and 1 bearish rules at once; the narrowing continues — the lead has already given back 5 points over 30 sessions, and a further 11-point move would eliminate JPM's advantage entirely.
What do the current signals say about JPM and VERA?
JPM: 3 bullish / 1 bearish, conflicted. VERA: 1 bullish / 2 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on JPM is Golden Cross Active (bullish, long horizon). On VERA it is Death Cross Active (bearish, long horizon).
Compare JPM and VERA with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.